Compare
HUTCHMED (China) Ltd vs Organogenesis Holdings Inc. vs BridgeBio Pharma, Inc. vs Insmed Inc
| Latest fiscal year | HUTCHMED (China) Ltd HCM | Organogenesis Holdings Inc. ORGO | BridgeBio Pharma, Inc. BBIO | Insmed Inc INSM |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $548.51M | $564.17M | $502.08M | $606.42M |
| Revenue growth (YoY) | -13.0% | +17.0% | +126.3% | +66.7% |
| Gross margin | 38.7% (computed) | n/a | n/a | 79.7% (computed) |
| Operating margin | -7.1% | 7.9% | -104.2% | -205.6% |
| Net margin | 83.3% | 6.6% | -146.0% | -210.5% |
| Net income | $456.91M | $37.03M | -$732.94M | -$1.28B |
| EPS (Diluted) | $0.52 | $0.15 | -$3.78 | -$6.42 |
| Operating cash flow | -$64.66M | -$10.31M | -$445.91M | -$935.01M |
| Free cash flow | -$78.81M | -$24.46M | -$447.01M | -$967.58M |
| Cash & equivalents | $71.33M | $93.68M | $570.12M | $510.44M |
| Total assets | $1.75B | $598.73M | $936.02M | $2.26B |
| Total liabilities | $501.83M | $164.81M | $3.01B | $1.53B |
| Shareholders' equity | $1.25B | $300.13M | -$2.09B | $738.98M |
| Return on year-end equity | 36.5% | 12.3% | n/a | -172.8% |
| Shares outstanding | n/a | 126.95M | 194.77M | 214.26M |
Revenue, most recent five fiscal years
| Fiscal year | HUTCHMED (China) Ltd | Organogenesis Holdings Inc. | BridgeBio Pharma, Inc. | Insmed Inc |
|---|---|---|---|---|
| Latest | $548.51M Ended 2025-12-31 | $564.17M Ended 2025-12-31 | $502.08M Ended 2025-12-31 | $606.42M Ended 2025-12-31 |
| 1 year earlier | $630.20M Ended 2024-12-31 | $482.04M Ended 2024-12-31 | $221.90M Ended 2024-12-31 | $363.71M Ended 2024-12-31 |
| 2 years earlier | $838.00M Ended 2023-12-31 | $433.14M Ended 2023-12-31 | $9.30M Ended 2023-12-31 | $305.21M Ended 2023-12-31 |
| 3 years earlier | $426.41M Ended 2022-12-31 | $450.89M Ended 2022-12-31 | $77.65M Ended 2022-12-31 | $245.36M Ended 2022-12-31 |
| 4 years earlier | $356.13M Ended 2021-12-31 | $467.36M Ended 2021-12-31 | $69.72M Ended 2021-12-31 | $188.46M Ended 2021-12-31 |